Sign inJoin free

Watch / Small Cap

BCAL Diagnostics close to commercialisation

4 June 20248:00

BCAL Diagnostics close to commercialisation

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key highlights:

  • BCAL Diagnostics successfully oversubscribed its AUD 10.5m fundraising for commercialised blood test.

  • The blood test will be a first for Australian market, acting alongside mammogram procedures for breast cancer detection.

  • BCAL Diagnostics set for future expansion with secured strong financial position, including a US market entry by end of 2025.

Jayne Shaw, co-founder of BCAL Diagnostics, reveals that the biotech firm has raised AUD 10.5m for the commercial launch of its blood test, focused on detecting breast cancer. The funds raised significantly oversubscribed initial intentions to generate AUD 5m for commercialisation of their test and further laboratory expansion. Gratitude is expressed towards existing and new shareholders for their overwhelming response.

Jayne continues to outline BCAL's offering, a blood test for breast cancer detection. The test, 14 years in the making, is expected to launch later this year, working alongside current mammogram procedures, and will mark a first in the Australian market. The BCAL blood test boasts a sensitivity rate of 90% and a specificity of 85%, offering a more streamlined approach to breast cancer detection. The firm cooperates with a solid network of clinicians and key opinion leaders to develop and improve the test, pushing forward with input from pioneering figures within the breast cancer clinical community.

Looking to the future, she discloses plans to roll out the test nationally by early 2025, and expansion into the US market, targeted through a laboratory-developed test, by the end of 2025. Regulatory hurdles for these plans are anticipated to be a straightforward process, with Nitro accreditation in progress and the Australian Therapeutic Goods Administration being aware of these movements. The raised funds secure the firm's strong financial position, allowing further research and development alongside commercialisation.

Full unedited transcript below:

0:00

Breast cancer biotech BCL diagnostics has raised $10.5 million in an oversubscribed round, the funds remarked for the commercial launch of its blood test in Australia later this year. For the details, co-founder and executive chair Jane Shore joining us now. Jane, welcome. Thanks for joining us again. Autoship is so, um, what what was the purpose of this of this placement. And in fact, I think it was, um, way oversubscribed.

0:25

Absolutely, yes. Our intention was to raise, um, $5 million, um, basically to fund the commercialization, the ongoing, um, expansion and not to accreditation of our laboratory. Um, as we announced in our foresee, uh, we had about $3 million left in the bank, and we were raising, uh, 5 million to take us to commercialization and revenue generation. So it was, uh, we've been overwhelmed by existing and many new shareholders, which were very grateful for. So, Jones, for those unfamiliar with what you do, this is obviously about screening for, uh, detection of breast cancer. So just talk us through what you're offering there, what you're planning to commercialize.

1:08

Okay. So, um, currently, the standard of care for, uh, the detection of breast cancer is a mammogram. And a mammogram has been the standard of care for the last 30 years. Um, myself and other members of the team have been working for the last 14 years to develop a blood test for breast cancer. So, um, we've had a blood test since 1989 for prostate cancer. The PSA, which many men would be aware of in the audience. So, um, 14 years of development and we will launch our blood test, uh, to detect breast cancer alongside initially a mammogram, which is the current standard of care.

1:50

All right. So, um, how effective is this blood test or what's the accuracy, if you like?

1:56

So the sensitivity, um, in all our research today is 90% and about specificity, specificity of 85%. And we're working with, um, a large group of clinicians, breast surgeons, oncologists and radiologists, um, around how sensitive they want the test to be for the product launch and for the, um, the use of the test. So we're working very closely with them, um, in the development and utility test. So how well received has it been clinically then?

2:31

Oh, clinically, we've been working with clinicians, uh, initially from Lifehouse in, in Sydney, and now we've got a network of about 50 key opinion leaders, uh, working with us to develop this test. Um, so currently, um, Doctor David Speakman, medical director of the MacCallum Centre in Melbourne, is the chair of our Key Opinion Leader network. And we've got breast surgeons from all over Australia, oncologists and radiologists. So, um, we've been very fortunate to work with a, um, leading group of key opinion leaders in the breast cancer clinical community. Jane, other than the mammogram, which she said was still being part of this testing process, um, is there any other technology that perhaps rivals what you have, or do you have a competitive advantage as such?

3:25

We will be the only artist is based on lipids. It's a lipid signature in the blood test in the blood. And, um, we are the only, uh, lipid, uh, signature for the detection of breast cancer. Um, there are other, um, there are other tests out there in terms of looking at proteomics. mRNA and billions of dollars have been spent on genomic technology. But this will be the first, um, blood test to detect breast cancer, uh, launched in Australia at this time. So, Jane, what is the next step towards that commercialisation then? And what sort of timeline do you have in mind?

4:04

Well, it's very exciting. It's been 14 years in the making. Um, so we'll be launching or generating revenue by the end of this year. We'll be launching the test in existing multidisciplinary breast care centres. So this is centres where you can have a mammogram, an ultrasound. Um, and it's a multidisciplinary approach with our existing, uh, key opinion leaders. Then uh, early 25 will roll that out nationally because we want this test to be available and accessible for all women, uh, throughout Australia. We've been working on a parallel entry market strategy into the US. We've undertaken a number of market entry, um, initiatives, reimbursement initiatives, and we'll be looking at, uh, partnering in the US through a clear laboratory at the end of 2025. Are there any regulatory hurdles to overcome at this point?

4:56

So we are launching through a in-house IVD process. So we own our own laboratory, um, in North Ryde. And we'll be going for our Nitro accreditation in September this year. And it's the Nitro accreditation that will give us the approvals to launch the test in the Australian market. We've been working with TGA for about the last, uh, about last four years. So they're very well aware of what we're doing and all the clinical and technical data files that we've been preparing for and after assessment will be used as part of our TGA registration process. But this was the quickest way for us to get the test, uh, into the market, um, at this time. And what about approval as far as breaking into the US market is concerned, the US again will enter that through, uh, it's called a laboratory developed test. So we'll partner with a clear lab or establish our own, and then we can start, um, making the

5:56

test available to clinicians in the, in the US. So it is a proven path to market. And in the meantime, what to conducting further R&D. Um, and trials perhaps mean how given your latest round of funding, are you expecting more is required?

6:14

Uh, we're going to have a very strong balance sheet now. Um, you know, um, we're we're very well funded and we're in a, in a great position. So the, uh, the board made the decision to, to, um, take the extra capital that was made available to us, um, to actually put us in a very strong financial position. Um, so we're going to continue with our, um, sample collection. We're collecting from ten Australian sites in Australia where women can participate in the sample collection. So if women would like to participate, um, if they go to the vehicle diagnostics website, they can register and be part of the samples. We are collecting all our samples, um, fresh from the from the sites. They're not from bio banks or anything like that. So they're real, real time samples. And then, uh, when we go to launch the test in the Australian market, we can start charging patients for the test, sending the, um, the samples to our laboratory,

7:14

and then return the results to the doctors and the clinicians. And what what's the likely cost? And would it be on the schedule?

7:22

Won't be on the schedule. Um, it will be an out of pocket cost, uh, initially at $300. Um, the price point for that. We've done many focus groups, um, on the price point. Obviously, we want it available for every woman everywhere. Um, and at the moment, if you have a contrast mammogram, which is another diagnostic tool with a mammogram, the average out-of-pocket expenses is about $300. So that's the price point that we've discussed with clinicians. Uh, consumer groups and advocacy groups at this time. We hope that would reduce as we continue to scale and leverage the test.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy